304 related articles for article (PubMed ID: 29105742)
21. Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study.
Limvorapitak W; Srisum-Ang T; Chimres C; Warnnissorn N; Kanitsap N
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e27-37. PubMed ID: 26796980
[TBL] [Abstract][Full Text] [Related]
22. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
Gupta L; Suku P; Dash A; Bose P; Sharma P; Mallik N; Sreedharanunni S; Varma N; Jandial A; Malhotra P; Sachdeva MUS
Curr Probl Cancer; 2024 Feb; 48():101025. PubMed ID: 37951052
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma.
Kumar S; Witzig TE; Greipp PR; Rajkumar SV
Br J Haematol; 2003 Jul; 122(2):272-4. PubMed ID: 12846897
[TBL] [Abstract][Full Text] [Related]
24. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
Pasqualetti P; Colantonio D; Casale R
Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
[TBL] [Abstract][Full Text] [Related]
26. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.
Sanoja-Flores L; Flores-Montero J; Puig N; Contreras-Sanfeliciano T; Pontes R; Corral-Mateos A; García-Sánchez O; Díez-Campelo M; Pessoa de Magalhães RJ; García-Martín L; Alonso-Alonso JM; García-Mateo A; Aguilar-Franco C; Labrador J; Barez-García A; Maiolino A; Paiva B; San Miguel J; Sobral da Costa E; González M; Mateos MV; Durie B; van Dongen JJM; Orfao A
Blood; 2019 Dec; 134(24):2218-2222. PubMed ID: 31697808
[No Abstract] [Full Text] [Related]
27. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
Dutoit JC; Vanderkerken MA; Verstraete KL
Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
[TBL] [Abstract][Full Text] [Related]
28. Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood.
Klimienė I; Radzevičius M; Matuzevičienė R; Sinkevič-Belliot K; Kučinskienė ZA; Pečeliūnas V
Int J Lab Hematol; 2021 Jun; 43(3):403-408. PubMed ID: 33185981
[TBL] [Abstract][Full Text] [Related]
29. Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.
Rifkin RM; Abonour R; Terebelo H; Shah JJ; Gasparetto C; Hardin J; Srinivasan S; Ricafort R; Nagarwala Y; Durie BG
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):368-76. PubMed ID: 25617035
[TBL] [Abstract][Full Text] [Related]
30. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.
Paiva B; Vidriales MB; Pérez JJ; Mateo G; Montalbán MA; Mateos MV; Bladé J; Lahuerta JJ; Orfao A; San Miguel JF; ;
Haematologica; 2009 Nov; 94(11):1599-602. PubMed ID: 19880781
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
32. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.
Lohr JG; Kim S; Gould J; Knoechel B; Drier Y; Cotton MJ; Gray D; Birrer N; Wong B; Ha G; Zhang CZ; Guo G; Meyerson M; Yee AJ; Boehm JS; Raje N; Golub TR
Sci Transl Med; 2016 Nov; 8(363):363ra147. PubMed ID: 27807282
[TBL] [Abstract][Full Text] [Related]
33. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
Schinke C; Qu P; Mehdi SJ; Hoering A; Epstein J; Johnson SK; van Rhee F; Zangari M; Thanendrarajan S; Barlogie B; Davies FE; Yaccoby S; Morgan GJ
Clin Cancer Res; 2018 Jun; 24(12):2913-2919. PubMed ID: 29563136
[No Abstract] [Full Text] [Related]
34. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and risk stratification in multiple myeloma.
van de Donk NW; Sonneveld P
Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
[TBL] [Abstract][Full Text] [Related]
36. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
[TBL] [Abstract][Full Text] [Related]
37. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
[TBL] [Abstract][Full Text] [Related]
38. Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms.
Vasco-Mogorrón MA; Campillo JA; Periago A; Cabañas V; Berenguer M; García-Garay MC; Gimeno L; Soto-Ramírez MF; Martínez-Hernández MD; Muro M; Minguela A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918790
[TBL] [Abstract][Full Text] [Related]
39. Correlation of multiparameter flow cytometry and bone marrow trephine immunohistochemistry in the identification and characterization of neoplastic plasma cells.
Menter T; Abdulsalam AH; Nadal-Melsio E; Yebra-Fernandez E; Flora RS; Ahmad R; Rahemtulla A; Naresh KN
Br J Haematol; 2017 Nov; 179(3):499-501. PubMed ID: 27378518
[No Abstract] [Full Text] [Related]
40. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
